{
  "abstract": "Autoimmune-related adverse effects may occur from monoclonal antibody medications though autoimmune encephalopathy is not a commonly reported reaction. Inhibiting the insulin-like growth factor 1 pathway has been shown to cause neurocognitive side effects. We report a case of a man in his early 60s who presented with neuropsychiatric changes after beginning teprotumumab for thyroid eye disease. He was diagnosed with teprotumumab-induced encephalopathy and ultimately treated with plasma exchange.",
  "authors": [
    {
      "affiliations": [
        "College of Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA"
      ],
      "name": "Alan Spicer"
    },
    {
      "affiliations": [
        "Lehigh Valley Health Network, Allentown, Pennsylvania, USA"
      ],
      "name": "Zuhair Siddiqui"
    },
    {
      "affiliations": [
        "Lehigh Valley Health Network, Allentown, Pennsylvania, USA"
      ],
      "name": "Ping-Hao Yang"
    },
    {
      "affiliations": [
        "Lehigh Valley Health Network, Allentown, Pennsylvania, USA"
      ],
      "name": "Ramya Punati"
    },
    {
      "affiliations": [
        "Lehigh Valley Health Network, Allentown, Pennsylvania, USA"
      ],
      "name": "Connie Tang"
    }
  ],
  "title": "From orbit to cortex: recognising teprotumumab-induced encephalopathy",
  "uid": "0b713e7c-76ce-5bec-a177-f5aae07af39d"
}